Skip to main content
SpringerLink
Log in

Neoadjuvant Chemotherapy and Radiation for Patients with Locally Unresectable Pancreatic Adenocarcinoma: Feasibility, Efficacy, and Survival

  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Background

We evaluated the feasibility and efficacy of neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic cancer.

Materials and Methods

From October 2000 to August 2006, 245 patients with pancreatic adenocarcinoma underwent surgical exploration at our institution. Of these, 78 patients (32%) had undergone neoadjuvant therapy for initially unresectable disease, whereas the remaining patients (serving as the control group) were explored at presentation (n = 167). All neoadjuvant patients received gemcitabine-based chemotherapy, often in conjunction with docetaxal and capecitabine in a regimen called GTX (81%). Seventy-five percent of neoadjuvant patients also received preoperative abdominal radiation (5,040 rad).

Results

Neoadjuvant patients were younger than control-group patients (60.8 vs 66.2 years, respectively, p < 0.002). Seventy-six percent of neoadjuvant patients were resected as compared to 83% of control patients (NS). Concomitant vascular resection was required in 76% of neoadjuvant patients but only 20% of NS (p < 0.01). Complications were more frequent in the neoadjuvant group (44.1 vs 30.9%, p < 0.05), and mortality was higher (10.2 vs 2.9%, p < 0.03). Among the neoadjuvant patients, all but one of the deaths were in patients that underwent arterial reconstruction. Mortality for patients undergoing a standard pancreatectomy without vascular resection was 0.8% in this series. Of patients resected, negative margins were achieved in 84.7% of neoadjuvant patients and 72.7% of NS. Within the cohort of neoadjuvant patients, radiation significantly increased the complication rate (13.3 vs 54.6%, p < 0.006), but did not affect median survival (512 vs 729 days, NS). Median survival for patients who received neoadjuvant therapy (503 days) was longer than NS that were found to be unresectable at surgery (192 days, p < 0.001) and equivalent to NS that were resected (498 days).

Conclusions

Resection rate, margin status, and median survivals were equivalent when neoadjuvant patients were compared to patients considered resectable by traditional criteria, demonstrating equal efficacy. Surgical resection with venous reconstruction following neoadjuvant therapy for patients with locally advanced pancreatic cancer can be performed with acceptable morbidity and mortality. This approach extended the boundaries of surgical resection and greatly increased median survival for the “inoperable” patient with advanced pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–130.

    Article  PubMed  Google Scholar 

  2. Mancuso A, Calabro F, Sternberg CN. Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol/Hematol 2006;58:231–241.

    Article  Google Scholar 

  3. Molinari M, Helton WS, Espat NJ. Palliative strategies for locally advanced unresectable and metastatic pancreatic cancer. Surg Clin North Am 2001;81:651–658.

    Article  PubMed  CAS  Google Scholar 

  4. Xiong HQ, Carr K, Abbruzzese JL. Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions. Drugs 2006;66(8):1059–1072.

    Article  PubMed  CAS  Google Scholar 

  5. Fine RL, Fogelman DR, Sherman W. The GTX regimen: A biochemically synergistic combination for advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 2003;Abst # 1129.

  6. Fine RL, Fogelman DR, Schreibman S, Guba S, Sharma J, Shapiro G. GTX chemotherapy for metastatic pancreatic cancer: Response, survival, and toxicity data. J Clin Oncol 2004;22:381s.

    Article  Google Scholar 

  7. Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade R, Chabot JC. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: A retrospective analysis. Cancer Chemother Pharmacol 2007 (in press).

  8. Fogelman DR, Chen J, Chabot JA, Allendorf JD, Schrope BA, Ennis RD, Schreibman SM, Fine RL. The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: From 5-fluorouracil to GTX. Surg Oncol Clin N Am 2004;13:711–736.

    Article  PubMed  Google Scholar 

  9. Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: A population-based study (United States). Cancer Causes Control 2006;17:403–409.

    Article  PubMed  Google Scholar 

  10. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA. Six hundred and fifty consecutive pancreaticoduodenectomies in the 1990’s: Pathology, complications, and outcomes. Ann Surg 1997;226:248–260.

    Article  PubMed  CAS  Google Scholar 

  11. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, Coleman J. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991;161:120–124.

    Article  PubMed  CAS  Google Scholar 

  12. Tashiro S, Uchino R, Hiraoka T, Tsuji T, Kawamoto S, Saitoh N, Yamasaki K, Miyauchi Y. Surgical indication and significance of portal vein resection in biliary and pancreatic cancer. Surgery 1991;109:481–487.

    PubMed  CAS  Google Scholar 

  13. Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA. Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13(8):1035–1046.

    Article  PubMed  Google Scholar 

  14. Poon RT, Fan ST. Opinions and commentary on treating pancreatic cancer. Surg Clin North Am 2001;81:625–636.

    Article  PubMed  CAS  Google Scholar 

  15. Evans DB, Lee JE, Pisters PWT. Pancreaticoduodenectomy (Whipple operation) and total pancreatectomy for cancer. In Nyhus LM, Baker RJ, Fischer JF, eds. Mastery of Surgery, 3rd ed. Boston: Little Brown, 1997, pp 1233–1249.

    Google Scholar 

  16. Holzman MD, Reintgen KL, Tyler DS, Pappas TN. The role of laparoscopy in the management of suspected pancreatic and periampullary malignancies. J Gastrointest Surg 1997;1:236–243.

    Article  PubMed  CAS  Google Scholar 

  17. Rumstadt B, Schwab M, Schuster K, Hagmuller E, Trede M. The role of laparoscopy in the preoperative staging of pancreatic carcinoma. J Gastrointest Surg 1997;1:245–250.

    Article  PubMed  CAS  Google Scholar 

  18. Jessup JM, Steele G Jr, Mayer RJ, Posner M, Busse P, Cady B, Stone M, Jenkins R, Osteen R. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 1993;128:559–564.

    PubMed  CAS  Google Scholar 

  19. Kamthan AG, Morris JC, Dalton J, Mandeli JP, Chesser MR, Leben D, Cooperman A, Bruckner HW. Combined modality therapy for stage II and stage III pancreatic carcinoma. J Clin Oncol 1997;15:2920–2927.

    PubMed  CAS  Google Scholar 

  20. Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, Savage PD, Tepper JE. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999;17:2208–2212.

    PubMed  CAS  Google Scholar 

  21. Epelbaum R, Rosenblatt E, Nasrallah S, Faraggi D, Gaitini D, Mizrahi S, Kuten A. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 2002;81:138–143.

    Article  PubMed  CAS  Google Scholar 

  22. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000;89:314–327.

    Article  PubMed  CAS  Google Scholar 

  23. Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J, Lawrence TS, McGinn CJ. Surgical resection following radiation therapy with concurrent ge mcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 2003;7:766–772.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

Grant support for this study was provided by I.W. Foundation.

Author information

Authors and Affiliations

  1. Department of Surgery, Columbia University College of Physicians and Surgeons, 630 West 168th St., New York, NY, 10032, USA

    John D. Allendorf, Margaret Lauerman, Aliye Bill, Mary DiGiorgi, Nicole Goetz, Beth Schrope & John A. Chabot

  2. Department of Pathology, Columbia University College of Physicians and Surgeons, 630 West 168th St., New York, NY, 10032, USA

    Efsevia Vakiani & Helen Remotti

  3. Department of Medicine, Columbia University College of Physicians and Surgeons, 630 West 168th St., New York, NY, 10032, USA

    William Sherman, Michael Hall & Robert L. Fine

  4. 161 Ft. Washington Ave., New York, NY, 10032, USA

    John D. Allendorf

Authors
  1. John D. Allendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margaret Lauerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aliye Bill
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mary DiGiorgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicole Goetz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Efsevia Vakiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Helen Remotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Beth Schrope
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. William Sherman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michael Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Robert L. Fine
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. John A. Chabot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John D. Allendorf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Allendorf, J.D., Lauerman, M., Bill, A. et al. Neoadjuvant Chemotherapy and Radiation for Patients with Locally Unresectable Pancreatic Adenocarcinoma: Feasibility, Efficacy, and Survival. J Gastrointest Surg 12, 91–100 (2008). https://doi.org/10.1007/s11605-007-0296-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-007-0296-7

Keywords

Search

Navigation